Overview

A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Status:
Recruiting
Trial end date:
2024-10-23
Target enrollment:
Participant gender:
Summary
The reason for this study is to determine if the study drug LY3471851 is safe and effective in adult participants with active ulcerative colitis (UC). The study will last about 52 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Nektar Therapeutics